Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

wet macular degeneration - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

wet macular degeneration

MONDO:0005417

Also known as:Senile macular degeneration, wetexudative senile macular degeneration of retinaneovascular age-related macular degeneration

Find Clinical TrialsTrials

Overview

A form of RETINAL degeneration in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.

Treatments2 FDA approved, newest 2024

Clinical Trials16 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for wet macular degeneration has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for wet macular degeneration, including AFLIBERCEPT-MRBB (AHZANTIVE, approved 2024) and RANIBIZUMAB-EQRN (CIMERLI, approved 2022).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

16 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, gene therapy, biologic therapy, and procedural interventions. Pipeline includes 4 PHASE3, 6 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT03011541](https://clinicaltrials.gov/study/NCT03011541)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:04 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Macular Degeneration (Wet and Dry) Fund

Premium/CopayClosedOperated by HealthWell Foundation

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of AHZANTIVE for managing wet macular degeneration?
→Are any of the 16 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	88	25%
Clinical study results	81	23%
Research summaries	65	19%
Laboratory research	41	12%
Testing and diagnosis research	35	10%
New treatment approaches	20	6%
Patient case studies	11	3%
Other research	7	2%

Kisho

wet macular degeneration

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

When vision fades: Rethinking wet AMD and the durability gap

EyePoint plummets on pivotal data for main drug

Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA

wet macular degeneration

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

When vision fades: Rethinking wet AMD and the durability gap

EyePoint plummets on pivotal data for main drug

Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA